ArticleJournal of cardiology cases2020
Successful transcatheter aortic valve implantation in a Jehovah's Witness patient with a small aortic root and severe leaflet calcification.
Article in Journal of cardiology cases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 69-year-old female Jehovah's Witness was diagnosed with symptomatic severe aortic stenosis (AS). Because the patient, who refused blood transfusion for religious reasons, had multiple comorbidities, such as thrombocytopenia due to liver cirrhosis, esophageal varices, and an old cerebral infarction, a decision to perform transcatheter aortic valve implantation (TAVI) was made. Preprocedural computed tomography showed a small aortic root and severe leaflet calcification, especially at the non-coronary cusp; therefore, the risk of annulus and Valsalva rupture was considered to be high. A 20-mm transcatheter heart valve (Edwards SAPIEN3; Edwards Lifesciences Corporation, Irvine, CA, USA) was successfully implanted using the transfemoral approach. To prevent blood transfusion, erythropoietin and sodium ferrous citrate were prescribed during the periprocedural period. The postprocedural course was uneventful, and the patient was discharged on postoperative day 10. TAVI, which is associated with a significantly lower need for transfusion compared with surgical aortic valve replacement, has recently been performed as a less invasive treatment for high- or intermediate-risk patients with AS. This case highlights the feasibility and safety of TAVI using a 20-mm transcatheter heart valve for a patient with severe AS, a small aortic root, and severe and eccentric leaflet calcification who refused blood transfusion. <
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.